Merck has chosen to use aluminum as an adjuvant in their Gardasil:
http://ilena-rosenthal.blogspot.com

Rocz Panstw Zakl Hig. 1993;44(1):73-80.Links
[Aluminum as an adjuvant in vaccines and post-vaccine
reactions][Article in Polish]
http://www.ncbi.nlm.nih.gov/sites/en...t=AbstractPlus

Fiejka M, Aleksandrowicz J.
Zakladu Badania Surowic, Warszawie.

Aluminium compounds have been widely used as adjuvants in prophylactic
and therapeutic vaccines. Adjuvants are able to stimulate the immune
system in a nonspecific manner, i.e. high antibody level can be
obtained with minimal dose of the antigen and with reduced number of
inoculations. Adjuvants use has been mostly empirically determined by
such factors as efficacy and safety. The mechanism of action of the
aluminium adjuvants is not completely understood and is very complex.
The basic factors of the mode of action: 1) the complex of antigen and
aluminium gel is more immunogenic in structure than free antigen, 2)
effect "depot"--The antigen stimulus last longer, 3) the production of
local granulomas. Vaccines adsorbed onto aluminium salts are a more
frequent cause of local post-vaccinal reactions than plain vaccines.
5-10% those vaccinated can develop a nodule lasting several weeks at
the injection site. In some rare cases the nodules may become
inflammatory and even turn into an aseptic abscess. The nodules
persisting more than 6 weeks may indicate development of aluminium
hypersensitivity. Finally aluminium adjuvant immunogens induce the
production of IgE antibodies.